Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp4 | Clinical case posters | ECTS2013

The impact of calcimimetic treatment on bone turnover in a renal patient with high turnover hyperparathyroid bone disease

Murray Barbara , Kinsella Sinead , McQuillan Rory , Watson Alan

Introduction: The availability of bone turnover markers (BTMs) that are kidney independent has facilitated the monitoring of bone turnover in renal patients with hyperparathyroid bone disease. The effects of Cinacalcet on BTMs and on the relationship between parathyroid hormone (PTH) and BTMs were studied.Methods: The formation marker procollagen type 1 N propeptide (P1NP) and resorption marker tartrate resistant acid phosphatase 5b (TRACP5b) were measur...

ba0004p105 | (1) | ICCBH2015

Refractory hypercalcaemia of malignancy: responsiveness to Denosumab and Zoledronate

Giri Dinesh , Ramakrishnan Renuka , Hayden James , Brook Lynda , Das Urmi , Mughal M Zulf , Selby Peter , Dharmaraj Poonam , Senniappan Senthil

Background: Hypercalcaemia secondary to malignancy is rare in children and adolescents. Parathyroid hormone related peptide (PTH-rP) secreted by malignant cells increases bone resorption and renal calcium retention causing hypercalcaemia. We report two cases of hypercalcaemia of malignancy refractory to treatment with pamidronate and corticosteroids but responsive to treatment with Denosumab and Zoledronic acid.Case 1: Presenting problem: A 17-year-old b...

ba0001oc6.4 | Mineralisation and energy metabolism | ECTS2013

Inhibition of PTH-induced vasorelaxation modulates its anabolic action

Gohin Stephanie , Chenu Chantal , Pitsillides Andrew , Arnett Timothy , Marenzana Massimo

The relationship between bone formation and blood flow is unclear. Recently, PTH was reported to activate production of nitric oxide (NO), a potent vasorelaxing agent, in endothelial cells and we and others have confirmed a strong vasorelaxing action of PTH in vivo in the mouse. Here, we tested the hypothesis that a potent NO synthase inhibitor (L-NAME: NG-nitro-L-arginine methyl ester) may alter the effect of intermittent PTH (iPTH) on b...

ba0003pp217 | Osteoporosis: evaluation and imaging | ECTS2014

An observational study investigating the prevalence of anaemia in hip fracture patients

Frankland Stuart , Gupta Abhaya

Introduction: The blood loss sustained during hip fracture repair can be significant and is associated with a high-risk of post-operative anaemia. Anaemia may exacerbate chronic cardiac and pulmonary conditions suffered by this aging population leading to increased morbidity and mortality.Objective: To assess the prevalence and severity of anaemia throughout hospital admission in patients admitted with a fractured neck of femur.Met...

ba0001pp127 | Calciotropic and phosphotropic hormones and mineral metabolism | ECTS2013

Hypercalcemia following high vitamin D loading dose

Lips Paul , Neradova Aegida , van Schoor Natasja , Vervloet Mark

Vitamin D deficiency is common in older persons and non-western immigrants. Vitamin D is often started in loading doses of 50 000 IU/ml solution. Though, generally considered safe, this highly concentrated solution carries some risks as is illustrated by the following cases. A woman of >80 years old was admitted with hypercalcemia, calcium 3.27 mmol/l. She complained of nausea, thirst and polyuria for 3 months. History included cholecystitis, atrial fibrillation, myocardia...

ba0003pp332 | Osteoporosis: treatment | ECTS2014

Denosumab therapy of osteoporosis in patients after solid organ transplantation and impaired renal function

Brunova Jana , Kratochvilova Simona

The therapy of osteoporosis in patients with end organ failure and after the transplantation (Tx) becomes more frequent problem with the better patients and graft survival rates. Moreover some of these patients have impaired renal function and therefore cannot use bisphosphonates. The supplementation therapy with calcium and/or vitamin D is frequently not sufficient to improve bone mass. The possible innovative therapy is Denosumab (Prolia inj.) - MAB to RANK, which is not con...

ba0006p124 | (1) | ICCBH2017

The treatment of Hyperphosphatemic Familial Tumoral Calcinosis

Khatchadourian Karine , Lawton Lou , Willis Baxter , Ward Leanne

Background: Hyperphosphatemic familial tumoral calcinosis (HFTC) is characterized by hyperphosphatemia and the formation of tumor-like extra-osseous calcifications. Tumors often necessitate surgical management although medical treatment may limit the need for surgical intervention. We present two cases of HFTC successfully managed with combination acetazolamide (ACTZ) and sevelamer carbonate.Case Report #1: A 5-year-old African boy with a loss-of-functio...

ba0001pp148 | Cancer and bone: basic, translational and clinical | ECTS2013

Direct administration of zoledronate acid improves bone structure in local osteoporotic lesion of ovariectomized rats

Matsuo Yohei , Kashii Masafumi , Sugiura Tsuyoshi , Morimoto Tokimitsu , Honda Hirotsugu , Kaito Takashi , Iwasaki Motoki , Yoshikawa Hideki

Objective: To examine the efficacy and safety of direct administration of zoledronate acid (ZOL) on local osteoporotic lesion of ovariectomized rats.Methods: Six weeks later after ovariectomy, 16 6-month-old female S.D. rats were divided into the two groups with no differences of body weight and BMD of the proximal tibia. In the group L, 50 μl ZOL at a dose of 67 μg/kg were locally injected into the bone marrow between the two dr...

ba0005p440 | Other diseases of bone and mineral metabolism | ECTS2016

Mice lacking periostin are resistant to bone microstructural alterations during lactation

Bonnet Nicolas , Brun Julia , Ferrari Serge

Periostin is a matricellular protein expressed in late osteoblasts/osteocytes, which levels increase in response to PTH and mechanical loading. In turn periostin contributes to modeling based bone formation while restraining bone remodeling. Periostin is also a substrate of cathepsin K and inhibition of periostin blunts the effects of cathepsin K inhibition on bone. Considering the important role of osteocytes and their cathepsin K expression on osteolysis during lactation, we...

ba0004oc19 | (1) | ICCBH2015

The VINE study: vitamin D in newborns: a randomized controlled trial comparing daily and bolus supplementation in breastfed infants of vitamin D deficient mothers

Huynh Julie , Lu Thao , Liew Danny , Doery James , Tudball Ronald , Jona Madeleine , Bhamjee Roisin , Rodda Christine

Objective: There is no published data to demonstrate the efficacy and safety of a single bolus dose vitamin D in breastfed infants of vitamin D deficient mothers. We evaluated the efficacy and safety of this alternative approach in newborn infants <4 months of age.Method: This single centre study was conducted from Aug 2013 to May 2014. Of 307 pregnant women diagnosed with vitamin D deficiency (25OHD<50 nmol/l) 70 were recruited. Their newborn in...